Evidence mapPaperPMID 39622650Full record

SynthesisJMIR dermatology2024

Cutaneous Adverse Effects From Diabetes Devices in Pediatric Patients With Type 1 Diabetes Mellitus: Systematic Review.

Alicia Podwojniak, Joseph Flemming, Isabella J Tan, Hira Ghani, Zachary Neubauer, Anne Jones

Abstract readSystematic Review
In one paragraph

Synthesis in JMIR dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alicia PodwojniakRowan-Virtua School of Osteopathic Medicine, 113 Laurel Rd, Stratford, NJ, 08084, United States, 1 (856) 566-6789.ORCID http://orcid.org/0009-0005-5109-2405
Joseph FlemmingRowan-Virtua School of Osteopathic Medicine, 113 Laurel Rd, Stratford, NJ, 08084, United States, 1 (856) 566-6789.ORCID http://orcid.org/0000-0002-9947-1456
Isabella J TanRutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States.ORCID http://orcid.org/0000-0002-5756-6609
Hira GhaniDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.ORCID http://orcid.org/0000-0001-9296-9609
Zachary NeubauerSidney Kimmel Medical College of Jefferson University, Philadelphia, PA, United States.ORCID http://orcid.org/0009-0006-4497-2866
Anne JonesRowan-Virtua School of Osteopathic Medicine, 113 Laurel Rd, Stratford, NJ, 08084, United States, 1 (856) 566-6789.ORCID http://orcid.org/0000-0002-8045-4357

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSIIs) are the current standard treatment devices for type 1 diabetes (T1D) management. With a high prevalence of T1D beginning in pediatrics and carrying into adulthood, insufficient glycemic control leads to poor patient outcomes. Dermatologic complications such as contact dermatitis, lipodystrophies, and inflammatory lesions are among those associated with CGM and CSII, which reduce glycemic control and patient compliance. Objective: This systematic review aims to explore the current literature surrounding dermatologic complications of CGM and CSII as well as the impact on patient outcomes. Methods: A systematic review of the literature was carried out using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines using 5 online databases. Included articles were those containing primary data relevant to human participants and adverse reactions to CGM and CSII devices in pediatric populations, of which greater than 50% of the sample size were aged 0-21 years. Qualitative analysis was chosen due to the heterogeneity of outcomes. Results: Following the application of exclusion criteria, 25 studies were analyzed and discussed. An additional 5 studies were identified after the initial search and inclusion. The most common complication covered is contact dermatitis, with 13 identified studies. Further, 7 studies concerned lipodystrophies, 5 covered nonspecific cutaneous changes, 3 covered unique cutaneous findings such as granulomatous reactions and panniculitis, and 2 discussed user acceptability. Conclusions: The dermatologic complications of CGM and CSII pose a potential risk to long-term glycemic control in T1D, especially in young patients where skin lesions can lead to discontinuation. Increased manufacturer transparency is critical and further studies are needed to expand upon the current preventative measures such as device site rotation and steroid creams, which lack consistent effectiveness.

Indexed as

Blood Glucose Self-MonitoringDiabetes Mellitus, Type 1Insulin Infusion SystemsAdolescentChildChild, PreschoolDermatitis, ContactHumansHypoglycemic AgentsInsulinLipodystrophySkin DiseasesHypoglycemic AgentsInsulincontact dermatitiscontinuous glucose monitoringinsulin pumpslipodystrophylipohypertrophytype 1 diabetes

Identifiers

PMID39622650
PMCPMC11587996

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.